Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study
This work is licensed under the Creative Commons Attribution 4.0 International License.
Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 2014; 20: 4115–27. doi: 10.3748/wjg.v20.i15.4115RazaASoodGKHepatocellular carcinoma review: current treatment, and evidence-based medicine20142041152710.3748/wjg.v20.i15.4115Open DOISearch in Google Scholar
Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011; CD004787. doi: 10.1002/14651858.CD004787.pub2OliveriRSWetterslevJGluudCTransarterial (chemo)embolisation for unresectable hepatocellular carcinoma2011CD00478710.1002/14651858.CD004787.pub2Open DOISearch in Google Scholar
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–90. doi: 10.1056/NEJMoa0708857LlovetJMRicciSMazzaferroVHilgardPGaneEBlancJFSorafenib in advanced hepatocellular carcinoma20083593789010.1056/NEJMoa0708857Open DOISearch in Google Scholar
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25–34. doi: 10.1016/s1470-2045(08)70285-7ChengALKangYKChenZTsaoCJQinSKimJSEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial200910253410.1016/s1470-2045(08)70285-7Open DOISearch in Google Scholar
Li Q, Su T, Zhang X, Pan Y, Ma S, Zhang L, et al. A real-world study of optimal treatment with anlotinib first-line therapy in advanced hepatocellular carcinoma. Cancer Manag Res 2022; 14: 3037–46. doi: 10.2147/cmar.S379911LiQSuTZhangXPanYMaSZhangLA real-world study of optimal treatment with anlotinib first-line therapy in advanced hepatocellular carcinoma20221430374610.2147/cmar.S379911Open DOISearch in Google Scholar
Chen XQ, Zhao YX, Zhang CL, Wang XT, Zhang X, Chen X, et al. Effectiveness and safety of anlotinib with or without PD-1 blockades in the treatment of patients with advanced primary hepatocellular carcinoma: a retrospective, real-world study in china. Drug Des Devel Ther 2022; 16: 1483–93. doi: 10.2147/dddt.S358092ChenXQZhaoYXZhangCLWangXTZhangXChenXEffectiveness and safety of anlotinib with or without PD-1 blockades in the treatment of patients with advanced primary hepatocellular carcinoma: a retrospective, real-world study in china20221614839310.2147/dddt.S358092Open DOISearch in Google Scholar
Murer F, Pozzan C, Peserico G, Farinati F. Capecitabine in advanced hepatocellular carcinoma. Dig Liver Dis 2016; 48: 1260–1. doi: 10.1016/j.dld.2016.06.037MurerFPozzanCPesericoGFarinatiFCapecitabine in advanced hepatocellular carcinoma2016481260110.1016/j.dld.2016.06.037Open DOISearch in Google Scholar
Trevisani F, Brandi G, Garuti F, Barbera MA, Tortora R, Casadei Gardini A, et al. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. J Cancer Res Clin Oncol 2018; 144: 403–14. doi: 10.1007/s00432-017-2556-6TrevisaniFBrandiGGarutiFBarberaMATortoraRCasadei GardiniAMetronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation20181444031410.1007/s00432-017-2556-6Open DOISearch in Google Scholar
Casadei Gardini A, Foca F, Scartozzi M, Silvestris N, Tamburini E, Faloppi L, et al. Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. Sci Rep 2017; 7: 42499. doi: 10.1038/srep42499Casadei GardiniAFocaFScartozziMSilvestrisNTamburiniEFaloppiLMetronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study201774249910.1038/srep42499Open DOISearch in Google Scholar
Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329–38. doi: 10.1055/s-2007-1007122LlovetJMBrúCBruixJPrognosis of hepatocellular carcinoma: the BCLC staging classification1999193293810.1055/s-2007-1007122Open DOISearch in Google Scholar
Gao Y, Liu P, Shi R. Anlotinib as a molecular targeted therapy for tumors. Oncol Lett 2020; 20: 1001–14. doi: 10.3892/ol.2020.11685GaoYLiuPShiRAnlotinib as a molecular targeted therapy for tumors20202010011410.3892/ol.2020.11685Open DOISearch in Google Scholar
Liang L, Hui K, Hu C, Wen Y, Yang S, Zhu P, et al. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells. J Exp Clin Cancer Res 2019; 38: 71. doi: 10.1186/s13046-019-1093-3LiangLHuiKHuCWenYYangSZhuPAutophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells2019387110.1186/s13046-019-1093-3Open DOISearch in Google Scholar
Tang X, Zheng Y, Jiao D, Chen J, Liu X, Xiong S, et al. Anlotinib inhibits cell proliferation, migration and invasion via suppression of c-MET pathway and activation of ERK1/2 pathway in H446 cells. Anticancer Agents Med Chem 2021; 21: 747–55. doi: 10.2174/1871520620666200718235748TangXZhengYJiaoDChenJLiuXXiongSAnlotinib inhibits cell proliferation, migration and invasion via suppression of c-MET pathway and activation of ERK1/2 pathway in H446 cells2021217475510.2174/1871520620666200718235748Open DOISearch in Google Scholar
Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol 2018; 19: 1338–50. doi: 10.1016/s1470-2045(18)30495-9FangWYangYMaYHongSLinLHeXCamrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials20181913385010.1016/s1470-2045(18)30495-9Open DOISearch in Google Scholar
Lan W, Zhao J, Chen W, Shang H, Peng J, Lin J. Anlotinib overcomes multiple drug resistant colorectal cancer cells via inactivating PI3K/AKT pathway. Anticancer Agents Med Chem 2021; 21: 1987–95. doi: 10.2174/1871520621666210112113852LanWZhaoJChenWShangHPengJLinJAnlotinib overcomes multiple drug resistant colorectal cancer cells via inactivating PI3K/AKT pathway20212119879510.2174/1871520621666210112113852Open DOISearch in Google Scholar
Yang C, Qin S. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. Cancer Med 2018; 7: 4570–83. doi: 10.1002/cam4.1664YangCQinSApatinib targets both tumor and endothelial cells in hepatocellular carcinoma2018745708310.1002/cam4.1664Open DOISearch in Google Scholar
Zhen L, Jiali C, Yong F, Han X, Hongming P, Weidong H. The efficacy and safety of apatinib treatment for patients with unresectable or relapsed liver cancer: a retrospective study. J Cancer 2018; 9: 2773–7. doi: 10.7150/jca.26376ZhenLJialiCYongFHanXHongmingPWeidongHThe efficacy and safety of apatinib treatment for patients with unresectable or relapsed liver cancer: a retrospective study201892773710.7150/jca.26376Open DOISearch in Google Scholar
Xie XH, Wang F, Lin XQ, Qin YY, Xie ZH, Zhang JX, et al. Anlotinib plus S-1 for patients with EGFR mutation-negative advanced squamous cell lung cancer with PS scores of 2–3 after progression of second-line or later-line treatment. Cancer Manag Res 2020; 12: 12709–14. doi: 10.2147/cmar.S278068XieXHWangFLinXQQinYYXieZHZhangJXAnlotinib plus S-1 for patients with EGFR mutation-negative advanced squamous cell lung cancer with PS scores of 2–3 after progression of second-line or later-line treatment202012127091410.2147/cmar.S278068Open DOISearch in Google Scholar
Xiang M, Yang X, Ren S, Du H, Geng L, Yuan L, et al. Anlotinib combined with S-1 in third- or later-line stage IV non-small cell lung cancer treatment: a phase II clinical trial. Oncologist 2021; 26: e2130–e5. doi: 10.1002/onco.13950XiangMYangXRenSDuHGengLYuanLAnlotinib combined with S-1 in third- or later-line stage IV non-small cell lung cancer treatment: a phase II clinical trial202126e2130e510.1002/onco.13950Open DOISearch in Google Scholar
Yang X, Xiang M, Geng L, Wen Y, Du X. Anlotinib combined with S-1 in the third-line treatment of stage IV non-small cell lung cancer: study protocol for phase II clinical trial. Asian Pac J Cancer Prev 2019; 20: 3849–53. doi: 10.31557/apjcp.2019.20.12.3849YangXXiangMGengLWenYDuXAnlotinib combined with S-1 in the third-line treatment of stage IV non-small cell lung cancer: study protocol for phase II clinical trial20192038495310.31557/apjcp.2019.20.12.3849Open DOISearch in Google Scholar
Song D, Song M, Bae S, Chung W, Jang J, Kim Y, et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol 2015; 50: 445–54. doi: 10.1007/s00535-014-0978-3SongDSongMBaeSChungWJangJKimYA comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis2015504455410.1007/s00535-014-0978-3Open DOISearch in Google Scholar
Zhou M, Chen X, Zhang H, Xia L, Tong X, Zou L, et al. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. Cancer Commun 2019; 39: 36. doi: 10.1186/s40880-019-0383-7ZhouMChenXZhangHXiaLTongXZouLChina National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy2019393610.1186/s40880-019-0383-7Open DOISearch in Google Scholar
Si X, Zhang L, Wang H, Zhang X, Wang M, Han B, et al. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. Thorac Cancer 2019; 10: 551–6. doi: 10.1111/1759-7714.12977SiXZhangLWangHZhangXWangMHanBManagement of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303201910551610.1111/1759-7714.12977Open DOISearch in Google Scholar
Sun Y, Zhou A, Zhang W, Jiang Z, Chen B, Zhao J, et al. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study). Hepatol Int 2021; 15: 621–9. doi: 10.1007/s12072-021-10171-0SunYZhouAZhangWJiangZChenBZhaoJAnlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)202115621910.1007/s12072-021-10171-0Open DOISearch in Google Scholar